Hengrui Medicine advances oncology pipeline, continues share repurchase

Jiangsu Hengrui Medicine Co., Ltd. and its subsidiaries have received clinical trial approval notices from the National Medical Products Administration for several drugs. These include SHR-9839 (sc), SHR-A2009, SHR-1826, HRS-4642 injection, adebrelimab injection, rekhertuzumab injection, SHR-A2102 injection, HRS-7058 capsules, and HRS-7058 tablets. This approval will lead to the commencement of clinical trials for these compounds, advancing the company's oncology pipeline.

In parallel, Jiangsu Hengrui Medicine announced the progress of its A-share repurchase program. As of November 21, 2025, the company had cumulatively repurchased 8,898,700 shares, representing 0.13% of its total share capital. The highest repurchase price was RMB 70.00/share, and the lowest was RMB 59.32/share, with a total expenditure of RMB 59,521.63 million (excluding transaction fees) for its employee stock ownership plan.

The company's latest repurchase on November 21, 2025, involved 250,000 shares at prices ranging from RMB 59.32 to RMB 59.72, totaling RMB 14,879,886. The repurchased shares are intended for its employee stock ownership plan, indicating continued efforts to enhance shareholder value and employee incentives.